BRCA2 and breast cancer: Of these patients 7/122 (6%) under surveillance had previously undergone germline BRCA1/BRCA2 mutation testing through clinical genetics due to a strong FH of BC or OC fulfilling prior standard clinical criteria for genetic testing.